Robert Galvin

Employment

• University of Minnesota Twin Cities Faculty, Assistant Professor
  2023 - Present
• University of Minnesota Twin Cities Professionals-in-Training, Medical Fellow
  2022 - 2022
• University of Minnesota Twin Cities Students, NIH-NRSA Med Fellow-GradProg
  2020 - 2022
• University of Minnesota Pediatric Hematology/Oncology Fellow
  2019 - Present
• University of Minnesota Twin Cities Professionals-in-Training, Medical Fellow
  2019 - 2020
• University of Minnesota Twin Cities Professionals-in-Training, Medical Resident
  2016 - 2018

Education

• Virginia Commonwealth University M.D.
  2012 - 2016

Projects & Funding

Projects & funding information is unavailable.

Publications (14)

• Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant
  Clinical Cancer Research 2026 DOI: 10.1158/1078-0432.CCR-25-3764
  +Save
• Cerebroretinal Microangiopathy with Calcifications and Cysts (CRMCC): A 5-Year Diagnostic Challenge
  Diagnostics 2026 DOI: 10.3390/diagnostics16101432
  +Save
• Subsequent Meningiomas Among Survivors of Childhood Cancer
  JAMA Network Open 2025 DOI: 10.1001/jamanetworkopen.2025.48715
  +Save
• A review of diffuse hemispheric glioma, H3 G34-mutant disease development, DNA repair, microenvironment, and treatments on the horizon
  npj Precision Oncology 2025 DOI: 10.1038/s41698-025-01070-w
  +Save
• Temporal trends of subsequent central nervous system malignancies among survivors of childhood cancer
  JNCI: Journal of the National Cancer Institute 2025 DOI: 10.1093/jnci/djaf005
  +Save
• Conditionally replicative adenovirus as a therapy for malignant peripheral nerve sheath tumors
  Molecular Therapy Oncology 2024 DOI: 10.1016/j.omton.2024.200783
  +Save
• Integration of Computational Pipeline to Streamline Efficacious Drug Nomination and Biomarker Discovery in Glioblastoma
  Danielle Maeser, Robert F. Gruener, Robert Thomas Galvin +7 more
  Cancers 2024 DOI: 10.3390/cancers16091723
  +Save
• Unraveling the immunologic vulnerabilities of diffuse hemispheric glioma, H3 G34-mutant.
  Robert Thomas Galvin, Negar Sadeghipour, Joanne Xiu +5 more
  Journal of Clinical Oncology 2024 DOI: 10.1200/JCO.2024.42.16_suppl.2082
  +Save
• Revealing Pan-Histology Immunomodulatory Targets in Pediatric Central Nervous System Tumors
  Robert Thomas Galvin, Sampreeti Jena, Danielle Maeser +2 more
  Cancers 2023 DOI: 10.3390/cancers15225455
  +Save
• MYO5A::FGFR1 represents a novel fusion event in pediatric low-grade glioma
  Neuro-Oncology Advances 2023 DOI: 10.1093/noajnl/vdad017
  +Save
• Characterizing Immune-Mediated Cytopenias After Allogeneic Hematopoietic Cell Transplantation for Pediatric Nonmalignant Disorders
  Transplantation and Cellular Therapy 2021 DOI: 10.1016/j.jtct.2021.01.015
  +Save
• Neurofibromatosis in the Era of Precision Medicine
  Current oncology reports 2021 DOI: 10.1007/s11912-021-01032-y
  +Save
• Concurrent Subcutaneous Panniculitis-like T-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia in 2 Pediatric Patients
  Journal of Pediatric Hematology/Oncology 2020 DOI: 10.1097/MPH.0000000000001921
  +Save
• Targeting H3K27-Altered Diffuse Midline Glioma with Combined MEK and HDAC Inhibition: Clinical Response and in Vitro Validation
  DOI: 10.20944/preprints202610.0262.v1
  +Save